Systematic review and network meta-analysis of 24 placebo-controlled b/tsDMARD trials in psoriatic arthritis: ACR20, MDA and PASDAS discriminated active drug from placebo better than DAPSA (eg MDA vs DAPSA OR 0.71 favouring MDA).
Meta-analysisn = 24 trials
Annfeldt et al. Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis